Muthukaruppaiah Suganya
1 
, Varadharajan Jayaprakash
1* , Vasudevan Manimoliyan Duraimavalavan
2, Mathew Gerry George
1 , Raghavan Padmanabhan
1, Sailapathy Sreedhar
1 1 Department of Nephrology, SRM Medical College and Research Centre, Kattankulathur, Tamilnadu, India
2 Department of Medical Oncology, SRM Medical College and Research Centre, Kattankulathur, Tamilnadu, India
Abstract
Multiple myeloma is a malignant monoclonal plasma cell disorder occurring predominantly in the elderly population. Outcomes of coronavirus disease 2019 (COVID-19) are worse in elderly, persons with comorbid conditions such as malignancy and patients who are on immunosuppressive therapy. Here we report a case, in which COVID-19 unravelled the diagnosis of multiple myeloma and myeloma cast nephropathy. Bortezomib-based two drug induction immunosuppression, was given during the peak of second wave of COVID-19, and it resulted in clinical improvement and partial remission of multiple myeloma.
Implication for health policy/practice/research/medical education:
Guidelines for induction immunosuppression treatment of hematologic malignancies such as myeloma are not available for a recently recovered patient from COVID-19. Post-COVID status should not discourage clinicians from administering induction immunosuppression for treatment for multiple myeloma.
Please cite this paper as: Suganya M, Jayaprakash V, Duraimavalavan VM, George MG, Padmanabhan R, Sreedhar S. Management of a newly diagnosed case of myeloma kidney in a recently COVID-19 recovered patient. J Renal Inj Prev. 2024; 13(2): e31948. doi: 10.34172/jrip.2022.31948.